EP1100521A4 - Nouvelle sous-unite beta du canal a potassium, c7f2-a - Google Patents

Nouvelle sous-unite beta du canal a potassium, c7f2-a

Info

Publication number
EP1100521A4
EP1100521A4 EP99937511A EP99937511A EP1100521A4 EP 1100521 A4 EP1100521 A4 EP 1100521A4 EP 99937511 A EP99937511 A EP 99937511A EP 99937511 A EP99937511 A EP 99937511A EP 1100521 A4 EP1100521 A4 EP 1100521A4
Authority
EP
European Patent Office
Prior art keywords
subunit
potassium channel
channel beta
novel potassium
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99937511A
Other languages
German (de)
English (en)
Other versions
EP1100521A1 (fr
Inventor
Rory Curtis
Maria Alexandra Glucksmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of EP1100521A1 publication Critical patent/EP1100521A1/fr
Publication of EP1100521A4 publication Critical patent/EP1100521A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
EP99937511A 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a Withdrawn EP1100521A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12302098A 1998-07-27 1998-07-27
PCT/US1999/016949 WO2000006183A1 (fr) 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a
US123020 2002-04-15

Publications (2)

Publication Number Publication Date
EP1100521A1 EP1100521A1 (fr) 2001-05-23
EP1100521A4 true EP1100521A4 (fr) 2002-10-09

Family

ID=22406262

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99937511A Withdrawn EP1100521A4 (fr) 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a

Country Status (6)

Country Link
EP (1) EP1100521A4 (fr)
JP (1) JP2002524030A (fr)
AU (1) AU5232799A (fr)
CA (1) CA2335643A1 (fr)
MX (1) MXPA01000952A (fr)
WO (1) WO2000006183A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363626A1 (fr) * 1999-02-23 2000-08-31 Icagen, Inc. Sous-unites de bk beta de canaux potassiques de famille slo
CN1329069A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人plp蛋白39和编码这种多肽的多核苷酸

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042575A2 (fr) * 1998-02-17 1999-08-26 Sanofi-Synthelabo GENE ET PROTEINE DE LA SOUS-UNITE β DU CANAL POTASSIUM ACTIVE PAR LE CALCIUM

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8951191A (en) * 1990-10-29 1992-05-26 Dekalb Plant Genetics Isolation of biological materials using magnetic particles
US5637470A (en) * 1994-05-13 1997-06-10 Merck & Co., Inc. Screening array using cells expressing recombinant α and β subunits of the mammalian large-conductance (maxi-K) potassium channel

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042575A2 (fr) * 1998-02-17 1999-08-26 Sanofi-Synthelabo GENE ET PROTEINE DE LA SOUS-UNITE β DU CANAL POTASSIUM ACTIVE PAR LE CALCIUM

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 28 September 1994 (1994-09-28), XP002208382, Database accession no. L26101 *
KNAUS HANS-GUNTHER ET AL: "Primary sequence and immunological characterization of beta-subunit of high conductance Ca-2+-activated K+ channel from smooth muscle.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 25, 1994, pages 17274 - 17278, XP002208380, ISSN: 0021-9258 *
MAJUMDER KUMUD ET AL: "Molecular cloning and functional expression of a novel potassium channel beta-subunit from human atrium.", FEBS LETTERS, vol. 361, no. 1, 1995, pages 13 - 16, XP002208381, ISSN: 0014-5793 *
OBERST CORINNA ET AL: "Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits.", ONCOGENE, vol. 14, no. 9, 1997, pages 1109 - 1116, XP001088992, ISSN: 0950-9232 *
See also references of WO0006183A1 *

Also Published As

Publication number Publication date
JP2002524030A (ja) 2002-08-06
EP1100521A1 (fr) 2001-05-23
AU5232799A (en) 2000-02-21
MXPA01000952A (es) 2002-08-20
CA2335643A1 (fr) 2000-02-10
WO2000006183A1 (fr) 2000-02-10

Similar Documents

Publication Publication Date Title
HUP0101269A3 (en) Potassium channel inhibitors
PL348039A1 (en) 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators
PL341642A1 (en) Novel macrolydes
AU133942S (en) Channel member
AU4411399A (en) Potassium channel inhibitors
EP1056765A4 (fr) Genes humains du canal potassique
EP1068213A4 (fr) Nouveaux siloxanes amino-organo-fonctionnels
ZA9811591B (en) Potassium channel openers
SG72958A1 (en) Band
GB9612829D0 (en) Potassium channel blockers
GB2337931B (en) Sunshade
GB2334853B (en) Engineering operations channel provision
EP1100521A4 (fr) Nouvelle sous-unite beta du canal a potassium, c7f2-a
AU2717399A (en) Two p domains potassium channel
EP1079848A4 (fr) Recepteur d'angiostatine
IL143148A0 (en) Potassium channel interactors and uses therefor
EP1097166A4 (fr) Compositions de polypeptides et de polynucleotides de canaux k
AU2532299A (en) Potassium channel polypeptide
AU3835499A (en) Potassium channel subunit
EP1077705A4 (fr) Agonistes du canal potassium
EP1347049A4 (fr) Nouveau canal de potassium
EP1347050A4 (fr) Nouveau canal potassique
SI1040097T1 (en) Potassium channel openers
EP1121379A4 (fr) GENES elk DE MAMMIFERE A CANAL POTASSIQUE
TW351069U (en) Novel helmet

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020823

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20050808